METRO-MINNESOTA COMMUNITY CLINICAL ONCOLOGY PROGRAM

Metro-Minnesota Community Clinical Oncology Program（MMCCOP）代表九家医院组成的联合体，通过其由NCI资助的社区医院肿瘤学项目（“CHOP”）和CCOP运作，开发了一种管理癌症患者的通用方法，并建立了识别、录入和跟踪患者治疗和癌症预防和控制方案的机制。该联合体有一个社区范围的计算机化数据管理系统，能够进行预期的数据收集。该社区提供PPO、HMO和商业医疗保健计划，所有这些都在这九家联盟医院中有代表。这九家医院每年平均有8900名新的分析性癌症患者。88名核心研究者代表肿瘤学、血液学、放射学、肿瘤学、泌尿学、妇科肿瘤学、神经学、耳鼻喉科、家庭医疗、普通和专科外科医生，他们在癌症项目开发和方案管理方面开展了广泛的合作。MMCCOP工作人员在肿瘤学和数据管理方面经过资格认证和培训，并参与了当前项目结构和操作的开发。在最近一个由NCI资助的资助年度（6/98-5/99），MMCCOP将344名新患者/参与者（209.9治疗学分/185.1癌症控制学分）纳入NCI批准的研究。MMCCOP旨在维持一个区域范围的社区和医院联盟，为社区提供癌症预防，控制和治疗的最新进展。这将通过以下方式实现：将CCOP扩大到已建立的外联社区;与医院、基金会、保险公司和综合服务网络合作，为参与临床试验提供资金和报销支助;增加初级保健医生的参与;提供发展所需的专业知识、资源和庞大的人口基础，通过与NCI，ECOG，M.D.的合作，实施和评估临床癌症治疗和对照试验。安德森、NSABP、RTOG、URCC和与NCCTG的试点项目;改进和扩大目前的MMCCOP数据管理和通信系统，以增加研究人员参与权责发生制、方案运作和研究基地活动的数量和程度;实施新的战略，以改善少数群体和服务不足群体的访问和参与;提高专业人士和非专业人士对CCOP和临床癌症试验益处的认识。根据过去的经验，两个大型预防试验的可用性，增加了一个新的医院和第六个研究基地，并改进了癌症控制实施模式，MMCCOP研究人员打算在第一年内将532名（4370学分）患者/参与者纳入NCI批准的癌症治疗和控制研究，目标是不断超过NCI对这两种类型研究的要求。在最后一次MMCCOP申请中所述的350例患者的预计增加被当时的审查视为“过于乐观”，但在资助的第一年（1995-96年）就超过了33例患者。该赠款第一年的目标仍然是乐观的，但考虑到该小组的专业知识、现有的协议、既定的系统以及医生和医院的大力支持，这是现实的。

The Metro-Minnesota Community Clinical Oncology Program (MMCCOP) represents a consortium of nine hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operation CCOP, has developed a common approach to the management of cancer patients and has an established mechanism for identifying, entering and following patients on treatment and cancer prevention and control protocols. The consortium has a community wide-computerized data management system capable of prospective data collection. The community offers PPOs, HMOs and commercial healthcare programs, all of which are represented among these nine consortium hospitals. Together, the nine hospitals see an average of 8900 new analytic cancer patients per year. The 88 core investigators, representing oncology, hematology, radiation, oncology, urology, gynecologic oncology, neurology, ENT, Family Practice, general and specialty surgeons, have worked extensively together on cancer program development and protocol management. The MMCCOP staff is qualified and trained in oncology and data management, and has been involved in the development of the current program structure and operation. During the most recent NCI-funded grant year (6/98-5/99), the MMCCOP entered 344 new patients/participants (209.9 treatment credits/185.1 cancer control credits) into NCI-approved studies. The MMCCOP intends to sustain a region wide community and hospital consortium, which provides the community with the most recent advances in cancer prevention, control and treatment. This will be accomplished through expansion of the CCOP into established outreach communities; work with hospitals, foundations, insurers and Integrated Service Networks (ISNs) to develop funding and reimbursement support for participation in clinical trials; increased involvement of primary care physicians; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, ECOG, M.D. Anderson, NSABP, RTOG, URCC and pilot project with the NCCTG; improve and expand the current MMCCOP data management and communication system to increase the number and liver of participation of the investigators in accrual, program operations and research base activities; implement new strategies to improve access and participation of minority and underserved groups; and increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. Based upon past experience, the availability of two large prevention trials, addition of a new hospital and a sixth research base, and improved cancer control implementation models, MMCCOP investigators intend to accrue 532 (4370 credits) patients/participants onto NCI-approved cancer treatment and control studies during the first year, with the goal of continually exceeding the NCI requirements for both types of studies. The projected accrual of 350 patients stated in the last MMCCOP application was viewed by reviews at that time as "overly optimistic", but was exceeded by 33 patients in the first year of funding (1995-96). The goal for the first year of this grant is again optimistic, but realistic given the expertise of the group, available protocols, the established systems and strong support of the physicians and hospitals.